Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$4.55M$4.55M+789.3% vs Q2 2021 Net Income-$6.76M-$6.76MN/M vs Q2 2021 EPS Diluted-$0.04-$0.04N/M vs Q2 2021 Gross Profit$4,338,000+1,020.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,062,000N/M Free Cash Flowderived-$7,159,000N/M Margins · derivedGross margin95.3%+19.7 pt vs Q2 2021
Operating margin-93.0%+1289.8 pt vs Q2 2021
Net margin-148.5%+786.6 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 11, 2022 · 42 d after period end